Effects of switching from imiglucerase to velaglucerase alfa without dose reduction nor wash out in type 1 Gaucher disease.

Authors	Christine Serratrice, Monia Bengherbia, Marine Alessandrini, Bernard Grosbois, Fabrice Camou, Yves Marie Pers, Michael Bismuth, Isabelle Marie, Nadia Belmatoug, Marc Berger, Comité d'Evaluation et de Traitement de la maladie de Gaucher
Journal	Blood cells, molecules & diseases (Blood Cells Mol Dis) 2014 Jun-Aug Vol. 53 Issue 1-2 Pg. 94-6 ISSN: 1096-0961 [Electronic] United States
PMID	24411065 (Publication Type: Letter)
Chemical References	Glucosylceramidase Velaglucerase alfa, human imiglucerase
Topics	Drug Substitution Enzyme Replacement Therapy Gaucher Disease (drug therapy) Glucosylceramidase (therapeutic use) Humans Time Factors Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!